PT  - JOURNAL ARTICLE
AU  - Elliott, Hannah R.
AU  - Bennett, Chloe L.
AU  - Caramaschi, Doretta
AU  - English, Sinead
TI  - Negative association between higher maternal body mass index and breastfeeding outcomes is not mediated by DNA methylation
AID  - 10.1101/2023.11.01.23297893
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.11.01.23297893
4099  - http://medrxiv.org/content/early/2023/11/01/2023.11.01.23297893.short
4100  - http://medrxiv.org/content/early/2023/11/01/2023.11.01.23297893.full
AB  - The benefits of breastfeeding for the health and wellbeing of both infants and mothers are well documented, yet global breastfeeding rates are low. One factor associated with low breastfeeding is maternal body mass index (BMI), which is used as a measure of obesity. The negative relationship between maternal obesity and breastfeeding is likely caused by a variety of social, psychological, and physiological factors. Maternal obesity may also have a direct biological association with breastfeeding through changes in maternal DNA methylation. Here, we investigate this potential biological association using data from a UK-based cohort study, the Avon Longitudinal Study of Parents and Children (ALSPAC). We find that pre-pregnancy body mass index (BMI) is associated with lower initiation to breastfeed and shorter breastfeeding duration. We conduct epigenome-wide association studies (EWAS) of maternal BMI and breastfeeding outcomes and candidate-gene analysis of methylation sites associated with BMI identified via previous meta-EWAS. We find that DNA methylation at cg11453712, annotated to PHTP1, is associated with maternal BMI. From our results, neither this association nor those at candidate-gene sites are likely to mediate the link between maternal BMI and breastfeeding.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of Bristol provide core support for ALSPAC. This publication is the work of the authors. SE, DC and HRE will serve as guarantors for the contents of this paper. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf); methylation data was supported by BBSRC BBI025751/1 and BB/I025263/1. HRE and DC are members of the Medical Research Council Integrative Epidemiology Unit at the University of Bristol, which is supported by the Medical Research Council and the University of Bristol (MC_UU_00011/5). SE was supported by a Royal Society Dorothy Hodgkin Fellowship (DH140236); and SE and CB received support from the University of Bristol Biological Sciences MSci project programme.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time. Consent for biological samples has been collected in accordance with the Human Tissue Act (2004).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe ALSPAC study website contains details of all the data that is available through a fully searchable data dictionary and variable search tool http://www.bristol.ac.uk/alspac/researchers/our-data/. ALSPAC data is available on request by application to the ALSPAC executive committee (ALSPAC-exec{at}bristol.ac.uk). The ALSPAC data management plan (available here: www.bristol.ac.uk/alspac/researchers/access/) describes in detail the policy regarding data sharing, which is through a system of managed open access.